SAN DIEGO -- The risk of progression from smoldering multiple myeloma to symptomatic disease decreased by 50% in patients treated with the anti-CD38 monoclonal antibody daratumumab (Darzalex), ...

Clinical trial led by UAB researcher supports approval of new, potentially curative treatment for multiple myeloma ...

The management of smoldering multiple myeloma (MM) is undergoing a significant transformation, driven by growing evidence that early intervention can meaningfully delay progression to active disease.

Each year, approximately 36,000 people are diagnosed with the disease in the United States, according to the American Cancer ...

TORONTO -- For some patients with multiple myeloma and their physicians, progression-free survival (PFS) is just as important as overall survival (OS), according to results from a cross-sectional ...

KRd showed superior PFS and deeper responses compared to VRd in newly diagnosed multiple myeloma patients, achieving higher complete response and MRD-negativity rates. The trial demonstrated ...

The approval was supported by data from the ongoing Phase III MajesTEC-3 study.

Please provide your email address to receive an email when new articles are posted on . You've successfully added to your alerts. You will receive an email when new content is published. Click Here to ...

Add Yahoo as a preferred source to see more of our stories on Google. A sign for the Food And Drug Administration is seen outside of the headquarters on July 20, 2020 in White Oak, Maryland. (Sarah ...

Rapid Novor Inc., a Canadian biotechnology leader, announced today that its diagnostic laboratory has received a provisional license from the Ontario Ministry of Health (MOH) for its EasyM® assay, ...

Johnson & Johnson’s standout trial results for its Tecvayli and Darzalex Faspro pairing in previously treated relapsed or ...

Mezigdomide (a CELMoD) combined with carfilzomib/dexamethasone met the phase 3 primary endpoint, delivering statistically ...